Exelixis (EXEL) Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Results for Exelixis’ next-generation tyrosine kinase inhibitor demonstrated an objective response rate of 38% and a disease control rate of 88% –
– Anti-tumor activity was observed in.
Planners are finalizing programming for the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting, to be held at the San Diego Convention Center, October 1-4, 2023, which will offer more than 2,000 research presentations and 300 scientific abstracts and nearly 200 exhibitors.
/PRNewswire/ At the 2023 ASCO annual meeting, investigators from OneOncology s clinical team will present Oral Abstracts using real-world data to evidence.